{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:58:39Z","timestamp":1740110319545,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.antiviral.2017.09.007","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T02:02:40Z","timestamp":1505786560000},"page":"184-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A pilot study to expand treatment of chronic hepatitis C in resource-limited settings"],"prefix":"10.1016","volume":"146","author":[{"given":"Poonam","family":"Mathur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Comstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"McSweegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nongthombam Suraj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamasundaran","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Recommendations for Testing, Managing, and Treating Hepatitis C","author":"AASLD-IDSA","key":"10.1016\/j.antiviral.2017.09.007_bib1"},{"issue":"8","key":"10.1016\/j.antiviral.2017.09.007_bib2","first-page":"533","article-title":"FibroScan in the diagnosis of hepatitis C virus infection","volume":"9","author":"Afdhal","year":"2013","journal-title":"Gastroenterol. Hepatol. (NY)"},{"key":"10.1016\/j.antiviral.2017.09.007_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1477-7517-11-27","article-title":"Injecting drug use in Manipur and Nagaland, Northeast India: injecting and sexual risk behaviours across age groups","volume":"11","author":"Armstrong","year":"2014","journal-title":"Harm Reduct. J."},{"issue":"3","key":"10.1016\/j.antiviral.2017.09.007_bib4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.23802","article-title":"Expanding access to HCV treatment - extension for community healthcare outcomes (ECHO) project: disruptive innovation in specialty care","volume":"52","author":"Arora","year":"2010","journal-title":"Hepatol"},{"issue":"4","key":"10.1016\/j.antiviral.2017.09.007_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MCG.0000000000000124","article-title":"Impact of provider type on hepatitis C outcomes with boceprevir-based and telaprevir-based regimens","volume":"49","author":"Backus","year":"2015","journal-title":"J.\u00a0Clin. Gastroenterol."},{"year":"2015","series-title":"Press Release: Cepheid Announces European Approval of Xpert HCV Viral Load","author":"Cepheid","key":"10.1016\/j.antiviral.2017.09.007_bib6"},{"issue":"2","key":"10.1016\/j.antiviral.2017.09.007_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jceh.2014.06.011","article-title":"Future of therapy for hepatitis C in India: a matter of accessibility and affordability?","volume":"4","author":"Dhiman","year":"2014","journal-title":"J.\u00a0Clin. Exp. Hepatol."},{"key":"10.1016\/j.antiviral.2017.09.007_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4236\/ojgas.2014.412052","article-title":"Comparison between FIB-4 Index and fibroscan as marker of fibrosis in chronic HCV infection in Egyptian patients","volume":"4","author":"El Nakeeb","year":"2014","journal-title":"Open J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2017.09.007_bib9","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1097\/QAI.0b013e31825eb27b","article-title":"Scale-up of HIV treatment through PEPFAR: a historic public health achievement","volume":"60","author":"El-Sadr","year":"2012","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"year":"2016","series-title":"Press Releases: U.S. Food and Drug Administration Approves Gilead's Epclusa\u00ae (Sofosbuvir\/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C","author":"Gilead Sciences, Inc","key":"10.1016\/j.antiviral.2017.09.007_bib10"},{"key":"10.1016\/j.antiviral.2017.09.007_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2015.01.004","article-title":"A\u00a0path to eradication of hepatitis C in low- and middle-income countries","volume":"119","author":"Graham","year":"2015","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2017.09.007_bib12","first-page":"19","article-title":"Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays","volume":"8","author":"Gupta","year":"2012","journal-title":"Asian J. Transfus. Sci."},{"issue":"5","key":"10.1016\/j.antiviral.2017.09.007_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLos Med."},{"issue":"18","key":"10.1016\/j.antiviral.2017.09.007_bib14","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jama.2016.1993","article-title":"Hepatitis C treatment delivery mandates optimizing available health care human resources: a case for task shifting","volume":"315","author":"Jayasekera","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.antiviral.2017.09.007_bib15","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2214-109X(14)70365-1","article-title":"Hepatitis C drug affordability","volume":"3","author":"Kamal-Yanni","year":"2015","journal-title":"Lancet Glob. Health"},{"year":"2017","series-title":"High Efficacy of HCV Treatment by Primary Care Providers: the ASCEND Study. Poster Session Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA","author":"Kattakuzhy","key":"10.1016\/j.antiviral.2017.09.007_bib16"},{"issue":"9973","key":"10.1016\/j.antiviral.2017.09.007_bib17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Directly acting triple drug anti-HCV therapy induces sustained virologic response with a six week regimen: a proof of concept phase 2a cohort study","volume":"385","author":"Kohli","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2017.09.007_bib18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nm0411-394a","article-title":"New organization pledges scientific expertise for viral outbreaks","volume":"17","author":"Mann","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2017.09.007_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2015.06.003","article-title":"The global virus Network: challenging chikungunya","volume":"120","author":"McSweegan","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.09.007_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1744-8603-4-6","article-title":"The 'diagonal' approach to Global Fund financing: a cure for the broader malaise of health systems?","volume":"4","author":"Ooms","year":"2008","journal-title":"Glob. Health"},{"issue":"8","key":"10.1016\/j.antiviral.2017.09.007_bib21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics. A randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.antiviral.2017.09.007_bib22","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","article-title":"Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV Co-infection","volume":"313","author":"Osinusi","year":"2015","journal-title":"JAMA"},{"year":"2016","series-title":"The United States President's Emergency Plan for AIDS Relief. PEPFAR Global Results","author":"PEPFAR","key":"10.1016\/j.antiviral.2017.09.007_bib23"},{"issue":"2","key":"10.1016\/j.antiviral.2017.09.007_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jceh.2014.06.001","article-title":"Consensus statement of HCV task force of the Indian national association for study of the liver (INASL). Part II: INASL recommendations for management of HCV in India","volume":"4","author":"Puri","year":"2014","journal-title":"J.\u00a0Clin. Exper. Hepatol."},{"issue":"9","key":"10.1016\/j.antiviral.2017.09.007_bib25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/cid\/cit037","article-title":"Effect of HIV on liver fibrosis among HCV-infected African Americans","volume":"56","author":"Silver","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2017.09.007_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(14)71045-X","article-title":"Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study","volume":"15","author":"Solomon","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2017.09.007_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001795","article-title":"A\u00a0public health approach to hepatitis C control in low- and middle-income countries","volume":"12","author":"Suthar","year":"2015","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.antiviral.2017.09.007_bib28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hep.27584","article-title":"The continuum of hepatitis C testing and care","volume":"61","author":"Viner","year":"2015","journal-title":"Hepatol"},{"author":"World Bank","key":"10.1016\/j.antiviral.2017.09.007_bib29"},{"year":"2014","series-title":"Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection","author":"World Health Organization","key":"10.1016\/j.antiviral.2017.09.007_bib30"},{"year":"2014","series-title":"Access to Antiretroviral Drugs in Low- and Middle-income Countries","author":"World Health Organization","key":"10.1016\/j.antiviral.2017.09.007_bib31"},{"year":"2016","series-title":"Viral Hepatitis C Treatment in India","author":"World Health Organization","key":"10.1016\/j.antiviral.2017.09.007_bib32"},{"year":"2017","series-title":"Hepatitis C","author":"World Health Organization","key":"10.1016\/j.antiviral.2017.09.007_bib33"},{"year":"2017","series-title":"In\u00a0Vitro Diagnostics and Laboratory Technology: Public Reports of WHO Prequalified IVDs","author":"World Health Organization","key":"10.1016\/j.antiviral.2017.09.007_bib34"},{"year":"2017","series-title":"Hepatitis C: Can We Treat All by 2020?","author":"World Health Organization","key":"10.1016\/j.antiviral.2017.09.007_bib35"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217303790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217303790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T14:52:44Z","timestamp":1575384764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217303790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":35,"alternative-id":["S0166354217303790"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.09.007","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot study to expand treatment of chronic hepatitis C in resource-limited settings","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}